STRO Sutro Biopharma, Inc. - Common Stock
NASDAQ · Biotechnology · Lihat di SEC EDGAR ↗ tutup Okt 2, 2026 10-K/10-Q Agu 12, 2026
$15,35
· % dari rentang 52 mgg
· di atas terendah
· ke tinggi
$0,77rendah 52m
$43,85tinggi 52m
Kapitalisasi Pasar (MRQ)
$254M
P/E (TTM)
-0.6
EPS (TTM)
$-26.71
Pendapatan (TTM)
$46M
lencana Anda
Rentang 52M
$1–$44
Peringkat Analis
BUY
Target Harga
$47
P/E
-0.6
ROE
266.8%
Margin Laba Bersih
-395.2%
Strip lencana Anda kosong — sematkan metrik di mana saja di halaman ini.
STRO Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
Harga
$15.35
Kapitalisasi Pasar (MRQ)
$254M
P/E (TTM)
-0.6
EPS (TTM)
$-26.71
Pendapatan (TTM)
$46M
ROE (TTM)
266.8%
Rentang 52M
$1–$44
STRO Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
rentang
batang
Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.
Pemecahan saham
| Tanggal ex-dividen | Pemecahan | Tipe |
|---|---|---|
| 3 Des. 2025 | 1-for-10 | Terbalik |
Tentang Sutro Biopharma, Inc. - Common Stock Tinjauan perusahaan dari Wikipedia
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.
Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers.
As of 2024 Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine-based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically validated targets for which the current standard of care is suboptimal.
Technology
Sutro's Xpress CF Platform is based on Stanford Professor James R. Swartz's patented Open Cell-Free Synthesis (OCFS) technology. XpressCF technology enables the parallel expression of hundreds of protein variants in less than 24 hours, providing a platform for the discovery and development of a wide variety of protein classes including cytokines, vaccine carrier-proteins, antibodies, and novel antibody-based proteins. The XpressCF+ platform allows for precise incorporation of non-natural amino acids into a protein sequence, and Sutro is using this technology to develop homogeneous site-specific antibody-drug conjugates (ADCs). Once identified, production of protein drug candidates can be scaled in Sutro's cGMP manufacturing facility located in San Carlos, CA.
Sutro's technology has also contributed to the formation of SutroVax, a vaccine spin off founded in 2015 that has raised over US$170 million in capital.
Collaborations
In July 2018, Sutro signed a collaboration and licensing agreement with Merck to discover and develop novel cytokine-based therapies for cancer and autoimmune disorders. Sutro received an upfront payment of $60 million and is eligible for milestone payments totaling up to $1.6 billion associated with the development and sale of all therapeutic candidates and all possible indications identified under the collaboration. In 2017, Sutro and Celgene announced they had refocused their 2014 immuno-oncology collaboration on four programs advancing through preclinical development, including an ADC program targeting B-Cell maturation antigen (BCMA).
Awards
The XpressCF Platform was awarded Best ADC Technology Platform at the World ADC in 2018, with Sutro as the runner up for Best New Drug Developer. Sutro was named one of Fierce Biotech's Fierce 15 in 2014. In 2015 was awarded the DiNA Outstanding Partner Award by the California Life Sciences Association.
== References ==
Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗
sektorHealthcare
industriBiotechnology
karyawan128
negaraUS
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Pendapatan$102M2016-12-31 → 2025-12-31
EPS$-22.492020-12-31 → 2025-12-31
Arus Kas Bebas·2018-12-31 → 2018-12-31
Margin bersih-395.2%2018-12-31 → 2025-12-31
Valuasi & Rasio
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
| Metrik | Tren 5 Tahun | STRO | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| P/E (TTM) | -0.6rata-rata 5T ≈-2.6 | ≈-2.6 | · | · | |
| P/S (TTM) | 5.6rata-rata 5T ≈4.6 | ≈4.6 | 48.5 | Kurang nilai | |
| P/B (MRQ) | -2.5rata-rata 5T ≈1.9 | ≈1.9 | · | · | |
| Price / Cash Flow (Harga / Arus Kas) | -0.7rata-rata 5T ≈23.8 | ≈23.8 | · | · | |
| Price / Tangible Book (Harga / Nilai Buku Berwujud) | 4.5rata-rata 5T ≈2.5 | ≈2.5 | · | · |
Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
| Metrik | Tren 5 Tahun | STRO | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Margin Operasi (TTM) | -319.6%rata-rata 5T ≈-189.3% | ≈-189.3% | -871.1% | Tingkat teratas | |
| Margin EBITDA (TTM) | -306.3%rata-rata 5T ≈-181.4% | ≈-181.4% | -871.1% | Tingkat teratas | |
| Margin Sebelum Pajak (TTM) | -395.5%rata-rata 5T ≈-194.8% | ≈-194.8% | -196.5% | Lemah | |
| Margin Laba Bersih (TTM) | -395.2%rata-rata 5T ≈-193.8% | ≈-193.8% | -871.2% | Tingkat teratas | |
| ROA (TTM) | -79.1%rata-rata 5T ≈-41.2% | ≈-41.2% | -39.4% | Lemah | |
| ROE (TTM) | 266.8%rata-rata 5T ≈-46.8% | ≈-46.8% | -45.3% | Tingkat teratas | |
| ROIC | 119.5%rata-rata 5T ≈-136.8% | ≈-136.8% | -19.2% | Tingkat teratas |
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
| Metrik | Tren 5 Tahun | STRO | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Rasio Lancar (MRQ) | 3.3rata-rata 5T ≈3.9 | ≈3.9 | 6.3 | Likuiditas rendah | |
| Rasio Cepat (MRQ) | 3.2rata-rata 5T ≈3.4 | ≈3.4 | 4.9 | Likuiditas rendah |
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
| Metrik | Tren 5 Tahun | STRO | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Revenue YoY (Pendapatan YoY) | 65.2%rata-rata 5T ≈37.3% | ≈37.3% | · | · | |
| Revenue CAGR 3Y (CAGR Pendapatan 3T) | 14.8%rata-rata 5T ≈22.7% | ≈22.7% | · | · | |
| Revenue CAGR 5Y (CAGR Pendapatan 5T) | 19.1% | · | · | · |
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
| Metrik | Tren 5 Tahun | STRO | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Asset Turnover (Perputaran Aset) | 0.4rata-rata 5T ≈0.2 | ≈0.2 | 0.0 | Tingkat teratas | |
| Receivables Turnover (Perputaran Piutang) | 16.3rata-rata 5T ≈8.0 | ≈8.0 | 3.9 | Tingkat teratas | |
| Revenue / Employee (Pendapatan Tahunan ÷ karyawan (jumlah karyawan, yfinance). Turunan — bukan konsep SEC-XBRL yang tersimpan.) | ≈$800.7K | · | · | · |
nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
Kejutan Rata-rata
-3.4%
Laporan Berikutnya
Nov 04, 2026
| Periode | Laporan | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|---|
| 30 Juni 2026 | Agu 5, 2026 | $-2.33 | $-2.24 | -4.1% |
| 31 Maret 2026 | Mei 14, 2026 | $-2.94 | $-3.85 | 23.6% |
| 31 Des. 2025 | $-5.29 | $-4.43 | -19.4% | |
| 30 Sep. 2025 | $-6.70 | $-4.23 | -58.5% | |
| 30 Juni 2025 | $-1.40 | $-4.10 | 65.9% | |
| 31 Maret 2025 | $-9.10 | $-7.22 | -26.1% | |
| 31 Des. 2024 | $-8.90 | $-8.48 | -5.0% |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $102M | $62M | $154M | $68M | $62M | $43M | $43M | $38M | $52M | |
| R&D Expense | $166M | $252M | $180M | $137M | $104M | $77M | $66M | $54M | $55M | |
| SG&A Expense | $41M | $48M | $63M | $60M | $56M | $37M | $33M | $21M | $16M | |
| Operating Expenses | $261M | $300M | $243M | $197M | $160M | $114M | $98M | $76M | $71M | |
| Operating Income | $-158M | $-238M | $-89M | $-129M | $-99M | $-71M | $-55M | $-37M | $-19M | |
| Interest Expense | · | · | · | · | · | · | · | $2M | $612.0K | |
| Other Non-op | · | · | · | · | · | · | · | $2M | $-77.0K | |
| Pretax Income | $-191M | $-225M | $-89M | $-117M | $-106M | $-32M | · | · | · | |
| Income Tax | $-93.0K | $2M | $18M | $2M | $0 | $103.0K | $0 | $0 | $0 | |
| Net Income | $-191M | $-227M | $-107M | $-119M | $-106M | $-32M | $-119M | $-35M | $-20M | |
| EPS (Basic) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 | $-0.99 | · | · | · | |
| EPS (Diluted) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 | $-0.99 | · | · | · | |
| Shares (Basic) | 8,497,798 | 7,736,734 | 60,163,542 | 50,739,185 | 46,119,089 | 32,573,469 | · | · | · | |
| Shares (Diluted) | 8,497,798 | 7,736,734 | 60,163,542 | 50,739,185 | 46,119,089 | 32,573,469 | · | · | · | |
| EBITDA | $-151M | $-231M | $-82M | $-123M | $-94M | $-67M | · | $-33M | · |
Neraca
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $58M | $190M | $69M | $47M | $30M | $206M | $5M | $125M | $22M | |
| Short-term Investments | $83M | $127M | $264M | $255M | $130M | $120M | $113M | $79M | · | |
| Receivables | $4M | $9M | $36M | $7M | $12M | $6M | $6M | $2M | $2M | |
| Prepaid Expense | $6M | $18M | $10M | $12M | $8M | $4M | $4M | $3M | $2M | |
| Current Assets | $151M | $343M | $422M | $353M | $219M | $378M | $129M | $210M | $26M | |
| PP&E (Net) | $11M | $18M | $22M | $25M | $23M | $13M | $10M | $11M | $14M | |
| PP&E (Gross) | $38M | $67M | $64M | $63M | $56M | $50M | $43M | $40M | $39M | |
| Accum. Depreciation | $27M | $49M | $42M | $38M | $33M | $37M | $34M | $29M | $25M | |
| Other Non-current Assets | $495.0K | $7M | $4M | $2M | $2M | $2M | $3M | $2M | $1M | |
| Total Assets | $174M | $387M | $471M | $407M | $341M | $394M | $156M | $223M | $41M | |
| Accounts Payable | $8M | $10M | $9M | $5M | $6M | $6M | $6M | $3M | $3M | |
| Accrued Liabilities | $15M | $13M | $15M | $13M | $11M | $9M | $6M | $6M | $4M | |
| Current Liabilities | $75M | $132M | $94M | $67M | $42M | $30M | $33M | $36M | $32M | |
| Capital Leases | $8M | $16M | $23M | $30M | $31M | · | · | · | · | |
| Other Non-current Liabilities | $2M | $2M | $2M | $119.0K | $146.0K | $481.0K | $134.0K | $102.0K | $14.0K | |
| Total Liabilities | $306M | $343M | $321M | $190M | $89M | $62M | $59M | $92M | $47M | |
| Long-term Debt | · | · | $4M | $16M | $25M | $25M | · | $15M | · | |
| Total Debt | · | · | $4M | $16M | $25M | $25M | · | $10M | · | |
| Common Stock | $9.0K | $8.0K | $61.0K | $58.0K | $46.0K | $46.0K | $23.0K | $23.0K | · | |
| Retained Earnings | $-978M | $-787M | $-559M | $-453M | $-333M | $-228M | $-196M | $-150M | $-115M | |
| AOCI | $19.0K | $39.0K | $21.0K | $-618.0K | $-314.0K | $129.0K | $165.0K | $-47.0K | · | |
| Stockholders' Equity | $-132M | $45M | $150M | $217M | $253M | $332M | $98M | $132M | $-109M | |
| Liabilities + Equity | $174M | $387M | $471M | $407M | $341M | $394M | $156M | $223M | $41M | |
| Shares Outstanding | 8,584,309 | 8,306,398 | 61,009,829 | 57,499,541 | 46,327,131 | 45,752,116 | 23,098,969 | 22,848,184 | 465,330 |
Arus Kas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $7M | $7M | $7M | $6M | $5M | $4M | $5M | $5M | $5M | |
| Stock-based Comp | $14M | $25M | $25M | $26M | $23M | $12M | $10M | $3M | $1M | |
| Restructuring | $13M | · | · | · | · | · | · | · | · | |
| Other Non-cash | $-7M | $4M | $-37M | $91M | $-4M | $-52M | · | $41M | · | |
| Operating Cash Flow | $-177M | $-192M | $-112M | $4M | $-82M | $-68M | $-65M | $13M | $-37M | |
| CapEx | · | · | · | · | · | · | · | $2M | $3M | |
| Investing Cash Flow | $45M | $219M | $-4M | $-35M | $-97M | $604.0K | $-51M | $-80M | $33M | |
| Debt Issued | · | · | · | · | · | · | · | $0 | $15M | |
| Net Debt Issued | · | · | · | · | · | · | · | $0 | · | |
| Stock Issued | $0 | $25M | $0 | $0 | · | $251M | $-327.0K | · | · | |
| Stock Repurchased | · | · | · | · | $7.0K | · | · | · | · | |
| Net Stock Activity | $0 | $25M | $12M | $56M | $-7.0K | $251M | · | · | · | |
| Financing Cash Flow | $44.0K | $94M | $138M | $48M | $3M | $269M | $-4M | $171M | $15M | |
| Net Change in Cash | $-132M | $121M | $22M | $17M | $-176M | $202M | $-120M | $103M | $10M | |
| Taxes Paid | $75.0K | $18M | $379.0K | $0 | $103.0K | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | · | · | $11M | · |
Profitabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -154.5% | -384.3% | -58.1% | -190.3% | -159.2% | -166.3% | · | -96.9% | · | |
| Net Margin | -186.5% | -366.6% | -69.5% | -175.9% | -170.6% | -75.2% | · | -91.9% | · | |
| Pretax Margin | -186.5% | -362.8% | -57.6% | -172.2% | · | · | · | · | · | |
| EBITDA Margin | -147.4% | -372.7% | -53.6% | -181.9% | -151.4% | -156.3% | · | -85.1% | · | |
| ROA | -68.1% | -53.0% | -24.3% | -31.9% | -28.7% | -11.7% | · | -26.8% | · | |
| ROE | 232.2% | -292.0% | -81.5% | -53.4% | -39.4% | -11.2% | · | 713.8% | · | |
| ROIC | 119.5% | -540.2% | -70.0% | -56.5% | · | · | · | · | · |
Likuiditas & Solvabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.0 | 2.6 | 4.5 | 5.3 | 5.2 | 12.8 | · | 5.8 | · | |
| Quick Ratio | 1.9 | 2.5 | 3.9 | 4.7 | 4.2 | 11.2 | · | 5.7 | · | |
| Debt / Equity | · | · | 0.0 | 0.1 | 0.1 | 0.1 | · | 0.1 | · | |
| LT Debt / Equity | · | · | 0.0 | 0.0 | 0.1 | 0.1 | · | 0.1 | · | |
| Interest Coverage | · | · | · | · | · | · | · | -22.9 | · |
Efisiensi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.1 | 0.4 | 0.2 | 0.2 | 0.2 | · | 0.3 | · | |
| Receivables Turnover | 16.3 | 2.8 | 7.1 | 6.9 | 6.9 | 7.2 | · | 18.7 | · |
Per Saham
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-15.43 | $0.54 | $2.45 | $3.77 | $5.45 | $7.26 | · | $5.76 | · | |
| Revenue / Share | $12.06 | $0.81 | $2.56 | $1.34 | · | · | · | · | · | |
| Cash Flow / Share | $-20.86 | $-2.49 | $-1.86 | $0.07 | · | · | · | · | · | |
| Cash / Share | $6.77 | $2.31 | $1.14 | $0.82 | $0.66 | $4.51 | · | $5.48 | · | |
| EPS (TTM) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 | $-0.99 | · | · | · |
Tingkat Pertumbuhan
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 65.2% | -59.6% | 126.8% | 9.5% | 44.8% | · | · | · | · | |
| Revenue CAGR 3Y | 14.8% | 0.09% | 53.2% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 19.1% | · | · | · | · | · | · | · | · |
Valuasi (TTM)
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $102M | $62M | $154M | $68M | $62M | $43M | $43M | $38M | · | |
| Net Income TTM | $-191M | $-227M | $-107M | $-119M | $-106M | $-32M | $-119M | $-35M | · | |
| Market Cap | $99M | $152M | $262M | $465M | $689M | $993M | · | $206M | · | |
| Enterprise Value | · | · | $-68M | $179M | $554M | $691M | · | $12M | · | |
| P/E | -0.5 | -0.1 | -2.4 | -3.4 | -6.5 | -21.9 | · | · | · | |
| P/S | 1.0 | 2.4 | 1.7 | 6.9 | 11.1 | 23.2 | · | 5.4 | · | |
| P/B | -0.7 | 3.4 | 1.7 | 2.1 | 2.7 | 3.0 | · | 1.6 | · | |
| P / Tangible Book | · | 3.4 | 1.7 | 2.1 | 2.7 | 3.0 | · | · | · | |
| P / Cash Flow | -0.6 | -0.8 | -2.3 | 130.9 | -8.4 | -14.6 | · | 16.2 | · | |
| P / FCF | · | · | · | · | · | · | · | 18.5 | · | |
| EV / EBITDA | · | · | 0.8 | -1.4 | -5.9 | -10.4 | · | -0.4 | · | |
| EV / FCF | · | · | · | · | · | · | · | 1.0 | · | |
| EV / Revenue | · | · | -0.4 | 2.6 | 8.9 | 16.2 | · | 0.3 | · | |
| Earnings Yield | -194.4% | -1597.8% | -41.5% | -29.1% | -15.4% | -4.6% | · | · | · |
Laporan Laba Rugi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $15M | $12M | $10M | $64M | $17M | $15M | $9M | $26M | $13M | $114M | $17M | $10M | $13M | $25M | $28M | |
| R&D Expense | $32M | $37M | $37M | $40M | $38M | $52M | $71M | $62M | $62M | $57M | $54M | $46M | $42M | $39M | $32M | $32M | |
| SG&A Expense | $8M | $8M | $9M | $9M | $10M | $13M | $9M | $14M | $12M | $13M | $17M | $15M | $15M | $16M | $15M | $15M | |
| Operating Expenses | $40M | $44M | $50M | $58M | $67M | $86M | $80M | $76M | $74M | $70M | $71M | $61M | $57M | $55M | $46M | $47M | |
| Operating Income | $-30M | $-30M | $-38M | $-48M | $-3M | $-69M | $-65M | $-68M | $-49M | $-57M | $43M | $-44M | $-46M | $-42M | $-21M | $-19M | |
| Pretax Income | $-39M | $-38M | $-47M | $-57M | $-12M | $-76M | $-70M | $-49M | $-48M | $-58M | $47M | $-47M | $-38M | $-50M | $-19M | $-24M | |
| Income Tax | $1.0K | $-15.0K | $-82.0K | $0 | $-18.0K | $7.0K | $2M | $0 | $8.0K | · | $16M | $2M | $151.0K | $395.0K | $0 | $2M | |
| Net Income | $-39M | $-38M | $-47M | $-57M | $-11M | $-76M | $-72M | $-49M | $-48M | $-58M | $31M | $-49M | $-39M | $-50M | $-19M | $-26M | |
| EPS (Basic) | $-2.33 | $-2.94 | $-20.77 | $-0.67 | $-1.35 | $-9.08 | $-27.63 | $-0.59 | $-0.59 | $-0.59 | $0.52 | $-0.81 | $-0.64 | $-0.85 | $-0.37 | $-0.55 | |
| EPS (Diluted) | $-2.33 | $-2.94 | $-20.77 | $-0.67 | $-1.35 | $-9.08 | $-27.63 | $-0.59 | $-0.59 | $-0.59 | $0.52 | $-0.81 | $-0.64 | $-0.85 | $-0.37 | $-0.55 | |
| Shares (Basic) | 16,571,602 | 13,082,355 | · | 84,869,864 | 8,511,985 | 8,364,294 | · | 82,043,671 | 81,224,628 | 61,457,793 | · | 60,599,025 | 60,339,475 | 58,723,432 | 52,345,732 | 46,957,196 | |
| Shares (Diluted) | 16,571,602 | 13,082,355 | · | 84,869,864 | 8,511,985 | 8,364,294 | · | 82,043,671 | 81,224,628 | 61,457,793 | · | 60,599,025 | 60,339,475 | 58,723,432 | 52,345,732 | 46,957,196 | |
| EBITDA | $-30M | $-28M | · | $-48M | $-3M | $-67M | · | $-68M | $-49M | $-55M | · | $-44M | $-46M | $-41M | $-21M | $-19M |
Neraca
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $54M | $74M | $58M | $66M | $64M | $106M | $190M | $175M | $91M | $65M | $69M | $82M | $235M | $62M | $97M | $79M | |
| Short-term Investments | $110M | $129M | $83M | $102M | $141M | $143M | $127M | $214M | $285M | $202M | $264M | $239M | $123M | $189M | $191M | $113M | |
| Receivables | $6M | $12M | $4M | $4M | $8M | $14M | $9M | $7M | $7M | $31M | $36M | $17M | $10M | $10M | $11M | $98M | |
| Prepaid Expense | $6M | $6M | $6M | $11M | $18M | $25M | $18M | $11M | $11M | $10M | $10M | $9M | $10M | $18M | $11M | $8M | |
| Current Assets | $176M | $221M | $151M | $182M | $232M | $287M | $343M | $406M | $443M | $355M | $422M | $381M | $412M | $304M | $347M | $332M | |
| PP&E (Net) | $8M | $9M | $11M | $13M | $15M | $17M | $18M | $19M | $19M | $21M | $22M | $22M | $24M | $24M | $24M | $24M | |
| PP&E (Gross) | · | · | $38M | · | · | · | $67M | · | · | · | $64M | · | · | · | · | · | |
| Accum. Depreciation | · | · | $27M | · | · | · | $49M | · | · | · | $42M | · | · | · | · | · | |
| Other Non-current Assets | $1M | $1M | $495.0K | $0 | $50.0K | $85.0K | $7M | $7M | $5M | $6M | $4M | $3M | $3M | $3M | $2M | $2M | |
| Total Assets | $194M | $242M | $174M | $210M | $262M | $321M | $387M | $452M | $489M | $403M | $471M | $432M | $465M | $358M | $401M | $386M | |
| Accounts Payable | $3M | $5M | $8M | $7M | $4M | $8M | $10M | $6M | $6M | $8M | $9M | $6M | $4M | $5M | $12M | $13M | |
| Accrued Liabilities | $6M | $5M | $15M | $13M | $12M | $12M | $13M | $13M | $10M | $7M | $15M | $11M | $10M | $6M | $10M | $8M | |
| Current Liabilities | $53M | $71M | $75M | $72M | $74M | $133M | $132M | $131M | $130M | $80M | $94M | $74M | $67M | $59M | $58M | $45M | |
| Capital Leases | $4M | $6M | $8M | $10M | $12M | $14M | $16M | $18M | $20M | $21M | $23M | $25M | $27M | $28M | $31M | $32M | |
| Other Non-current Liabilities | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | · | · | $133.0K | $142.0K | |
| Total Liabilities | $298M | $309M | $306M | $297M | $294M | $347M | $343M | $341M | $337M | $305M | $321M | $319M | $310M | $173M | $171M | $177M | |
| Total Debt | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $7M | $10M | |
| Common Stock | $17.0K | $17.0K | $9.0K | $85.0K | $85.0K | $84.0K | $8.0K | $82.0K | $82.0K | $62.0K | $61.0K | $61.0K | $60.0K | $60.0K | $55.0K | $49.0K | |
| Retained Earnings | $-1.05B | $-1.02B | $-978M | $-931M | $-874M | $-863M | $-787M | $-714M | $-666M | $-618M | $-559M | $-590M | $-541M | $-503M | $-418M | $-399M | |
| AOCI | $-58.0K | $-101.0K | $19.0K | $33.0K | $-13.0K | $-9.0K | $39.0K | $106.0K | $-163.0K | $-113.0K | $21.0K | $7.0K | $16.0K | $-107.0K | $-1M | $-1M | |
| Stockholders' Equity | $-103M | $-67M | $-132M | $-87M | $-32M | $-26M | $45M | $111M | $152M | $98M | $150M | $112M | $155M | $185M | $230M | $209M | |
| Liabilities + Equity | $194M | $242M | $174M | $210M | $262M | $321M | $387M | $452M | $489M | $403M | $471M | $432M | $465M | $358M | $401M | $386M | |
| Shares Outstanding | 16,576,205 | 16,566,803 | 8,584,309 | 85,101,749 | 84,720,047 | 84,349,041 | 8,306,398 | 82,395,350 | 81,861,584 | 62,456,546 | 61,009,829 | 60,900,704 | 60,471,041 | 60,161,801 | 54,631,360 | 48,674,232 |
Arus Kas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $5M | $6M | $6M | $7M | $6M | $6M | $6M | $6M | $7M | $6M | $7M | $7M | |
| Restructuring | · | $0 | $1M | $3M | $1M | $8M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $-7M | · | · | · | $647.0K | · | · | · | $-14M | · | · | · | $-19M | · | · | |
| Operating Cash Flow | $-38M | $-42M | $-26M | $-38M | $-45M | $-68M | $-72M | $-65M | $9M | $-65M | $14M | $-34M | $-31M | $-61M | $66M | $-3M | |
| Investing Cash Flow | $19M | $-45M | $19M | $40M | $3M | $-16M | $87M | $147M | $-80M | $64M | $-24M | $-114M | $66M | $67M | $-78M | $48M | |
| Stock Issued | · | · | $0 | $0 | · | · | $0 | $0 | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-418.0K | $103M | $-64.0K | $102.0K | $-60.0K | $66.0K | $-24.0K | $1M | $96M | $-3M | $-3M | $-6M | $138M | $9M | $30M | $5M | |
| Net Change in Cash | $-19M | $16M | $-8M | $2M | $-42M | $-84M | $16M | $84M | $26M | $-4M | $-13M | $-153M | $173M | $15M | $18M | $50M | |
| Taxes Paid | $1.0K | $-15.0K | $64.0K | $0 | $4.0K | $7.0K | $2M | $2.0K | $15M | $10.0K | · | · | · | · | · | · |
Profitabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -303.8% | -204.2% | · | -499.9% | -5.2% | -393.8% | · | -797.2% | -189.4% | -435.1% | · | -260.1% | -443.5% | -333.3% | -84.3% | -69.0% | |
| Net Margin | -391.6% | -265.0% | · | -586.6% | -18.0% | -436.6% | · | -572.6% | -186.8% | -447.5% | · | -291.2% | -370.0% | -394.9% | -77.5% | -92.6% | |
| Pretax Margin | -391.6% | -265.1% | · | -586.6% | -18.1% | · | · | -572.6% | -186.8% | -447.5% | · | -280.3% | -368.6% | -391.8% | -77.5% | -83.7% | |
| EBITDA Margin | -303.8% | -195.4% | · | -499.9% | -5.2% | -382.9% | · | -797.2% | -189.4% | -421.5% | · | -260.1% | -443.5% | -320.5% | -84.3% | -69.0% | |
| ROA | -16.9% | -13.7% | · | -17.2% | -3.1% | -21.0% | · | -11.0% | -10.1% | -15.3% | · | -11.8% | -9.1% | -15.1% | -5.1% | -7.0% | |
| ROE | 56.9% | 83.0% | · | -474.8% | -19.1% | -210.4% | · | -43.6% | -31.3% | -41.1% | · | -28.8% | -21.2% | -24.7% | -7.6% | -10.1% | |
| ROIC | 28.9% | 44.3% | · | 55.5% | 10.4% | · | · | -61.1% | -32.0% | · | · | -40.7% | -30.0% | -23.0% | · | -9.8% |
Likuiditas & Solvabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.1 | · | 2.5 | 3.1 | 2.2 | · | 3.1 | 3.4 | 4.5 | · | 5.2 | 6.1 | 5.1 | 5.9 | 7.4 | |
| Quick Ratio | 3.2 | 3.0 | · | 2.4 | 2.9 | 2.0 | · | 3.0 | 2.9 | 3.8 | · | 4.6 | 5.5 | 4.4 | 5.1 | 6.5 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 |
Efisiensi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | · | 0.0 | 0.2 | 0.0 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | |
| Receivables Turnover | 1.4 | 1.1 | · | 1.8 | 8.5 | 0.8 | · | 0.7 | 3.0 | 0.6 | · | 1.2 | 0.2 | 1.2 | 2.1 | 0.5 |
Per Saham
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-6.23 | $-4.04 | · | $-1.03 | $-0.38 | $-0.31 | · | $1.35 | $1.86 | $1.57 | · | $1.84 | $2.56 | $3.08 | $4.21 | $4.29 | |
| Revenue / Share | $0.59 | $1.11 | · | $0.11 | $0.75 | $0.21 | · | $0.10 | $0.32 | $0.21 | · | $0.28 | $0.17 | $0.22 | $0.48 | $0.60 | |
| Cash Flow / Share | · | $-3.23 | · | · | · | $-0.82 | · | · | · | $-1.05 | · | · | · | $-1.04 | · | · | |
| Cash / Share | $3.28 | $4.45 | · | $0.77 | $0.76 | $1.26 | · | $2.12 | $1.11 | $1.04 | · | $1.34 | $3.89 | $1.04 | $1.77 | $1.63 | |
| EPS (TTM) | $-26.71 | $-25.73 | · | $-38.73 | $-38.65 | $-37.89 | · | $-1.25 | $-1.47 | $-1.52 | · | $-2.89 | $-2.45 | $-2.36 | $-2.59 | $-2.89 |
Valuasi (TTM)
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $46M | $100M | · | $106M | $104M | $66M | · | $161M | $169M | $154M | · | $49M | $57M | $75M | $70M | $53M | |
| Net Income TTM | $-181M | $-154M | · | $-217M | $-209M | $-245M | · | $-124M | $-124M | $-115M | · | $-172M | $-143M | $-130M | $-123M | $-134M | |
| Market Cap | $550M | $413M | · | $74M | $60M | $55M | · | $285M | $240M | $353M | · | $211M | $281M | $278M | $303M | $254M | |
| Enterprise Value | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $23M | $72M | |
| P/E | -1.2 | -1.0 | · | -0.0 | -0.0 | -0.0 | · | -2.8 | -2.0 | -3.7 | · | -1.2 | -1.9 | -2.0 | -2.1 | -1.8 | |
| P/S | 12.0 | 4.1 | · | 0.7 | 0.6 | 0.8 | · | 1.8 | 1.4 | 2.3 | · | 4.3 | 4.9 | 3.7 | 4.3 | 4.8 | |
| P/B | -5.3 | -6.2 | · | -0.8 | -1.9 | -2.1 | · | 2.6 | 1.6 | 3.6 | · | 1.9 | 1.8 | 1.5 | 1.3 | 1.2 | |
| P / Tangible Book | · | · | · | · | · | · | · | 2.6 | 1.6 | 3.6 | · | 1.9 | 1.8 | 1.5 | 1.3 | 1.2 | |
| P / Cash Flow | · | -9.8 | · | · | · | -0.8 | · | · | · | -5.5 | · | · | · | -4.6 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.3 | 1.3 | |
| Earnings Yield | -80.5% | -103.3% | · | -4451.7% | -5443.7% | -5829.2% | · | -36.1% | -50.2% | -26.9% | · | -83.3% | -52.7% | -51.1% | -46.7% | -55.5% |
Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Pendapatan | $102M | $62M | $154M | $68M | $62M |
| Margin Operasi % | -154.5% | -384.3% | -58.1% | -190.3% | -159.2% |
| Laba Bersih | $-191M | $-227M | $-107M | $-119M | $-106M |
| EPS Dilusian | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Utang / Ekuitas | · | · | 0.0 | 0.1 | 0.1 |
| Rasio Lancar | 2.0 | 2.6 | 4.5 | 5.3 | 5.2 |
| Rasio Cepat | 1.9 | 2.5 | 3.9 | 4.7 | 4.2 |
Tidak ada data untuk laporan ini
Data fundamental belum cukup untuk membuat laporan ini.
Pemilik institusional (13F) 110 pengaju · $537.9M total · Per tanggal 30 Juni 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
Pemegang
110
Nilai yang dipegang
$537.9M
Posisi baru
43
Posisi yang keluar
16
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 43 (+15 vs Kuartal sebelumnya) | 16 (+8 vs Kuartal sebelumnya) | 23 (+1 vs Kuartal sebelumnya) | 19 (+6 vs Kuartal sebelumnya) | +2.1M |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | $43.320.887 | 1.304.846 | 8,05% | Saham |
| BVF INC/IL | $41.559.362 | 1.251.788 | 7,73% | Saham |
| Affinity Asset Advisors, LLC | $38.926.568 | 1.172.487 | 7,24% | Saham |
| BlackRock, Inc. | $37.272.146 | 1.122.655 | 6,93% | Saham |
| SAMSARA BIOCAPITAL, LLC | $35.287.350 | 1.062.872 | 6,56% | Saham |
| Kynam Capital Management, LP | $28.968.926 | 872.558 | 5,39% | Saham |
| ORBIMED ADVISORS LLC | $24.698.941 | 743.944 | 4,59% | Saham |
| Balyasny Asset Management L.P. | $23.610.578 | 711.162 | 4,39% | Saham |
| VANGUARD CAPITAL MANAGEMENT LLC | $23.048.071 | 694.219 | 4,28% | Saham |
| EVENTIDE ASSET MANAGEMENT, LLC | $19.430.698 | 585.262 | 3,61% | Saham |
| Velan Capital Investment Management LP | $17.003.712 | 512.160 | 3,16% | Saham |
| Woodline Partners LP | $15.206.563 | 458.029 | 2,83% | Saham |
| ADAR1 Capital Management, LLC | $13.413.265 | 404.014 | 2,49% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $12.940.982 | 389.692 | 2,41% | Saham |
| MILLENNIUM MANAGEMENT LLC | $12.150.270 | 365.972 | 2,26% | Saham |
| STATE STREET CORP | $10.158.503 | 305.979 | 1,89% | Saham |
| Merck & Co., Inc. | $9.042.053 | 272.351 | 1,68% | Saham |
| ACUTA CAPITAL PARTNERS, LLC | $8.972.333 | 270.251 | 1,67% | Saham |
| AMERIPRISE FINANCIAL INC | $8.123.011 | 244.669 | 1,51% | Saham |
| Point72 Asset Management, L.P. | $7.895.856 | 237.827 | 1,47% | Saham |
| KVP Capital Advisors, LP | $7.522.290 | 226.575 | 1,40% | Saham |
| UBS Group AG | $6.922.599 | 208.512 | 1,29% | Saham |
| TWO SIGMA INVESTMENTS, LP | $6.696.042 | 201.688 | 1,24% | Saham |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $6.559.058 | 197.562 | 1,22% | Saham |
| MARSHALL WACE, LLP | $5.818.167 | 175.246 | 1,08% | Saham |
| Nuveen, LLC | $5.577.500 | 167.997 | 1,04% | Saham |
| JPMORGAN CHASE & CO | $5.323.560 | 159.627 | 0,99% | Saham |
| GOLDMAN SACHS GROUP INC | $4.953.971 | 149.216 | 0,92% | Saham |
| VANGUARD GROUP INC | $4.347.844 | 375.786 | 0,81% | Saham |
| NORTHERN TRUST CORP | $4.180.976 | 125.933 | 0,78% | Saham |
| Seven Fleet Capital Management LP | $3.794.182 | 159.118 | 0,71% | Saham |
| Qube Research & Technologies Ltd | $3.539.452 | 106.610 | 0,66% | Saham |
| VANGUARD FIDUCIARY TRUST CO | $3.460.502 | 104.232 | 0,64% | Saham |
| CITADEL ADVISORS LLC | $3.385.238 | 101.965 | 0,63% | Saham |
| MACKENZIE FINANCIAL CORP | $3.146.264 | 94.767 | 0,58% | Saham |
| RENAISSANCE TECHNOLOGIES LLC | $2.865.957 | 86.324 | 0,53% | Saham |
| Invesco Ltd. | $1.902.526 | 57.305 | 0,35% | Saham |
| Y-Intercept (Hong Kong) Ltd | $1.855.183 | 55.879 | 0,34% | Saham |
| Squarepoint Ops LLC | $1.843.895 | 55.539 | 0,34% | Saham |
| XTX Topco Ltd | $1.732.011 | 52.169 | 0,32% | Saham |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1.636.826 | 49.302 | 0,30% | Saham |
| Sigma Planning Corp | $1.494.664 | 45.020 | 0,28% | Saham |
| Bank of New York Mellon Corp | $1.373.451 | 41.369 | 0,26% | Saham |
| BARCLAYS PLC | $1.226.872 | 36.954 | 0,23% | Saham |
| BANK OF AMERICA CORP /DE/ | $1.199.848 | 36.140 | 0,22% | Saham |
| Fisher Asset Management, LLC | $1.171.794 | 35.295 | 0,22% | Saham |
| Elmind Capital, LP | $1.063.628 | 32.037 | 0,20% | Saham |
| D. E. Shaw & Co., Inc. | $1.000.250 | 30.128 | 0,19% | Saham |
| Trexquant Investment LP | $917.515 | 27.636 | 0,17% | Saham |
| BNP PARIBAS FINANCIAL MARKETS | $909.116 | 27.383 | 0,17% | Saham |
Aktivis & pemilik 5%+ 1 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| SVLSF V, LLC, SV Life Sciences Fund V, L.P., SV Life Sciences Fund V Strategic Partners, L.P., SV Life Sciences Fund V (GP), L.P., ILSF III, LLC, International Life Sciences Fund III (GP), L.P., International Life Sciences Fund III Co-Investment, L.P., International Life Sciences Fund III (LP1), L.P., International Life Sciences Fund III Strategic Partners, L.P. | 9 Okt. 2018 | · | Pengajuan awal | Investasi pasif | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Orang dalam perusahaan 30 orang dalam · 16 pejabat · 15 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Jane Chung | Chief Executive Officer | 4 Maret 2026 M | 21.285 | 1 | 0 | $10.000 |
| William J Newell | CEO | 5 Maret 2025 M | 292.531 | 0 | 0 | $0 |
| Gregory K. Chow | CFO | 2 Juni 2026 M | 4.725 | 1 | 0 | $15.998 |
| Edward C Albini | CFO AND SECRETARY | 15 Mei 2025 M | 160.805 | 0 | 0 | $0 |
| Hans-Peter Gerber | CHIEF SCIENTIFIC OFFICER | 18 Sep. 2026 M | 12.367 | 1 | 0 | $13.600 |
| David Pauling | Chief Admin. Ofcr. & GC | 4 Maret 2026 M | 9.748 | 1 | 0 | $10.003 |
| Barbara Leyman | Chief Business Officer | 8 Juli 2025 M | 16.056 | 0 | 0 | $0 |
| Venkatesh Srinivasan | CHIEF TECH OP OFFICER | 1 Mei 2025 M | 53.686 | 0 | 0 | $0 |
| Anne Elizabeth Borgman | CHIEF MEDICAL OFFICER | 1 Mei 2025 M | 97.452 | 0 | 0 | $0 |
| Linda A Fitzpatrick | CHIEF PEOPLE & COMM. OFFICER | 1 Mei 2025 M | 119.744 | 0 | 0 | $0 |
| Nicki Vasquez | CHIEF PORT. STRAT & ALNCE OFCR | 29 Jan. 2024 M | 14.279 | 0 | 0 | $0 |
| Brunilda Shtylla | Chief Business Officer | 28 Agu 2023 S | 0 | 0 | 0 | $0 |
| Trevor Hallam | Pres. Rsrch & Cf. Sctific Ofcr | 14 April 2023 M | 100.368 | 0 | 0 | $0 |
| Anik Shabbir | Chief Technical Ops. Officer | 3 Maret 2023 M | 40.827 | 0 | 0 | $0 |
| Arturo Molina MD | Chief Medical Officer | 5 Maret 2022 M | 37.736 | 0 | 0 | $0 |
| Stephen Worsley | Chief Business Officer | 29 Jan. 2019 A | · | 0 | 0 | $0 |
| Heidi Hunter | Direktur | 5 Juni 2026 A | · | 0 | 0 | $0 |
| Michael Dybbs | Direktur | 5 Juni 2026 A | · | 0 | 0 | $0 |
| Jon Marc Wigginton | Direktur | 5 Juni 2026 A | · | 0 | 0 | $0 |
| Sukhi Jagpal | Direktur | 5 Juni 2026 A | · | 0 | 0 | $0 |
| Joseph M Lobacki | Direktur | 5 Juni 2026 A | · | 0 | 0 | $0 |
| Daniel H Petree | Direktur | 5 Juni 2026 A | 18.601 | 0 | 0 | $0 |
| Connie Matsui | Direktur | 5 Juni 2026 A | 50.000 | 1 | 0 | $40.000 |
| James P Panek | Direktur | 5 Juni 2026 A | · | 0 | 0 | $0 |
| John Gordon Freund | Direktur | 6 Juni 2024 A | 56.327 | 0 | 0 | $0 |
| Shalini Sharp | Direktur | 6 Juni 2022 A | · | 0 | 0 | $0 |
| Daniel Janney | Direktur | 17 Juni 2019 A | 1.944.901 | 0 | 0 | $0 |
| Michael Jay Ross | Direktur | 1 Okt. 2018 C | 18.248 | 0 | 0 | $0 |
| Bryan V Lawlis | Direktur | 26 Sep. 2018 A | · | 0 | 0 | $0 |
| CELGENE CORP /DE/ | Pemilik 10% | 1 Okt. 2018 C | 1.726.197 | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Kepemilikan ETF Dimiliki oleh 16 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,41% | 5.891 SH | 2 Okt. 2026 | Harian |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,18% | 29.395 SH | 2 Okt. 2026 | Harian |
| IWC · iShares Trust | 0,07% | 53.859 SH | 11 Sep. 2026 | Harian |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,03% | 11.715 SH | 19 Agu 2026 | Harian |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 91.894 SH | 19 Agu 2026 | Harian |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,01% | 21.700 SH | 2 Okt. 2026 | Harian |
| RSSL · Global X Funds | 0,01% | 7.595 NS | 31 Juli 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 177.152 SH | 19 Agu 2026 | Harian |
| VHT · VANGUARD WORLD FUND | 0,01% | 47.358 SH | 19 Agu 2026 | Harian |
| IWM · iShares Trust | 0,01% | 411.674 SH | 11 Sep. 2026 | Harian |
| IWO · iShares Trust | 0,00% | 23.235 SH | 11 Sep. 2026 | Harian |
| ITOT · iShares Trust | 0,00% | 29.448 SH | 11 Sep. 2026 | Harian |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 501.524 SH | 19 Agu 2026 | Harian |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2.670 SH | 19 Agu 2026 | Harian |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 1.330 SH | 19 Agu 2026 | Harian |
| IWN · iShares Trust | · | 128.703 SH | 11 Sep. 2026 | Harian |
STRO Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
peringkat · 20 analis
BELI
Target median
$50.00
+225,7%
6 30,0%
Beli Kuat
12 60,0%
Beli
1 5,0%
Tahan
1 5,0%
Jual
0 0,0%
Jual Kuat
Target Harga 12 Bulan
13 analis · 2026-10-01Target rata-rata $47.23 +207,7%
Sekarang
Harga saat ini $15.35
Rendah$10.00
Rata-rata$47.23
Tinggi$61.00
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
Dasar FY, harga per penutupan akhir tahun fiskal terakhir setiap perusahaan.
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| STRO | $99M | -0.5 | 65.2% | -186.5% | 232.2% | · |
| TLSI | · | · | · | · | · | · |
| IMRX | · | -5.2 | · | · | -45.3% | · |
| ANIK | $133M | -12.6 | -5.9% | -9.6% | -7.5% | 56.6% |
| EVMN | $540M | -1.5 | 85.7% | -529.8% | -401.2% | · |
| CAMP | $318M | -2.3 | 436.5% | -2298.5% | -183.4% | · |
| PALI | $375M | -7.8 | · | · | -25.4% | · |
| GLSI | $300M | -14.7 | · | · | -2159.7% | · |
| QTTB | $43M | 1.4 | · | 55.5% | 200.3% | · |
| IVVD | $697M | -8.2 | 110.5% | -98.2% | -36.9% | · |
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Sumber: SEC 10-Q diajukan Agu 12, 2026